Literature DB >> 3980281

Primary cancers of extrahepatic biliary passages.

B Mittal, M Deutsch, S Iwatsuki.   

Abstract

We analyzed the records of 22 patients with cancers of extrahepatic biliary passages (EHBP) to understand their natural histories and patterns of failure and to evaluate the effectiveness of various treatments. None of the preoperative investigations consistently defined the entire extent of tumor. Percutaneous transhepatic cholangiography (PTHC) was the most helpful (100%) in accurately defining the site of ductal obstruction. Computed tomography was helpful in diagnosing liver metastases in 53% and primary tumor mass in 23% of patients. The most common sites of tumor failure or persistence were: liver (67%), tumor bed (56%), peritoneum (22%), porta hepatis and lymph nodes (17%). The median survival for the entire group was 6.8 months. Surgery plays an important role in managing these tumors and in defining tumor extent for subsequent adjuvant irradiation. Patients receiving radiation doses greater than or equal to 70 TDF had a longer median survival (11 months) than patients receiving less than 70 TDF (4.4 months). All three patients, who were alive and free of disease greater than 1 year, received radiation doses greater than or equal to 70 TDF. From our data, it is difficult to comment on the effectiveness of chemotherapy. We have made suggestions regarding radiation volume and doses to various structures. The need for entering these patients into multi-institutional clinical trials is stressed.

Entities:  

Mesh:

Year:  1985        PMID: 3980281     DOI: 10.1016/0360-3016(85)90320-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  24 in total

1.  Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases.

Authors:  J C Flickinger; A H Epstein; S Iwatsuki; B I Carr; T E Starzl
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

Review 2.  Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma.

Authors:  Saleh Abbas; Charbel Sandroussi
Journal:  HPB (Oxford)       Date:  2013-01-08       Impact factor: 3.647

3.  Antitumor effect of the paclitaxel-eluting membrane in a mouse model.

Authors:  Jin-Seok Park; Seok Jeong; Don Haeng Lee; Jin Hee Maeng; In Suh Park; Sangsoo Park
Journal:  Oncol Lett       Date:  2018-07-17       Impact factor: 2.967

4.  Radical surgery for right-sided klatskin tumor.

Authors:  P Neuhaus; A Thelen
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

5.  Extended resections for hilar cholangiocarcinoma.

Authors:  P Neuhaus; S Jonas; W O Bechstein; R Lohmann; C Radke; N Kling; C Wex; H Lobeck; R Hintze
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

Review 6.  The role of chemotherapy in the treatment of bile duct cancer.

Authors:  R A Oberfield; R L Rossi
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

7.  Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies.

Authors:  Yoshifumi Kawarada; Bidhan C Das; Tatsushi Naganuma; Masami Tabata; Hiroki Taoka
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

8.  Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization.

Authors:  Seiji Kawasaki; Hiroshi Imamura; Akira Kobayashi; Terumasa Noike; Shiro Miwa; Shin-ichi Miyagawa
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

9.  Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.

Authors:  Ling Xu; Martin Hausmann; Wolfgang Dietmaier; Silvia Kellermeier; Theresa Pesch; Manuela Stieber-Gunckel; Elisabeth Lippert; Frank Klebl; Gerhard Rogler
Journal:  BMC Cancer       Date:  2010-06-18       Impact factor: 4.430

10.  Radiotherapy of cholangiocarcinoma: the roles for primary and adjuvant therapies.

Authors:  T Shiina; S Mikuriya; T Uno; T Toita; S Serizawa; J Itami; S Kawai; M Tani
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.